Psilocybin-assisted Therapy for Phantom Limb Pain

Double-blind, randomised, parallel-group pilot (n=20) testing a single 25 mg oral psilocybin dose versus 100 mg niacin in people with chronic phantom limb pain; outcomes include pain measures and behavioural and neural responses assessed with psychophysics and fMRI.

Primary aims are safety and reduction in pain scores; secondary assessments include mood, attitudes, and neural correlates of pain with close medical and psychological follow-up in a supportive setting.